Paris, France | December 24, 2025 — Sanofi announced that it has entered into a definitive agreement to acquire Dynavax Technologies Corporation in a cash transaction valued at approximately $2.2 billion. The acquisition adds HEPLISAV-B®, a marketed adult hepatitis B vaccine, and Z-1018, a Phase 1/2 shingles vaccine candidate, to Sanofi’s vaccines portfolio, significantly strengthening its position in adult immunization
Science Significance
From a scientific standpoint, the transaction brings together complementary vaccine technologies with the potential to address major unmet needs in adult infectious disease prevention. HEPLISAV-B® is differentiated by its two-dose regimen administered over one month, enabling faster and higher seroprotection compared with traditional three-dose hepatitis B vaccines given over six months. The vaccine combines recombinant hepatitis B surface antigen with Dynavax’s proprietary TLR9 agonist adjuvant, which enhances immune response in adults, including populations that respond less robustly to conventional vaccines. In addition, the inclusion of Z-1018, a shingles vaccine candidate in early clinical development, extends Sanofi’s research focus into next-generation adjuvanted vaccines designed to improve durability and breadth of immune protection.
Regulatory Significance
Regulatorily, the acquisition involves both marketed and investigational biologics, placing it squarely within GxP-intensive operations. HEPLISAV-B® is already approved and marketed in the United States, with established post-marketing surveillance, pharmacovigilance, and cGMP manufacturing requirements. Integrating Dynavax’s vaccine operations will require harmonization of quality systems, manufacturing controls, and regulatory reporting across organizations. The deal is subject to customary regulatory approvals, including antitrust clearance under the Hart-Scott-Rodino Act and other foreign regulatory filings, underscoring the importance of regulatory compliance and governance throughout the transaction lifecycle
Business Significance
Advertisement
Strategically, the acquisition accelerates Sanofi’s ambition to expand its adult vaccines franchise by combining Dynavax’s assets with Sanofi’s global development, manufacturing, and commercial scale. Under the terms of the agreement, Sanofi will acquire all outstanding Dynavax shares for $15.50 per share in cash, funded from available cash resources, with closing expected in the first quarter of 2026. The transaction is not expected to impact Sanofi’s 2025 financial guidance, while providing long-term growth potential through expanded indications, geographic reach, and lifecycle management of HEPLISAV-B®, as well as advancement of the shingles candidate and other pipeline programs.
Patients’ Significance
For patients, particularly adults at risk of hepatitis B infection, the acquisition has meaningful implications. In the United States alone, tens of millions of adults remain unvaccinated against hepatitis B, leaving them vulnerable to chronic infection that can progress to cirrhosis or liver cancer. The broader availability and promotion of a rapid, two-dose vaccine regimen may improve vaccination completion rates and protection. Additionally, continued investment in a next-generation shingles vaccine could benefit older adults, for whom shingles can lead to severe pain, long-term nerve damage, and other serious complications.
Policy Significance
At a policy level, the transaction aligns with public health priorities emphasizing adult immunization, disease prevention, and healthcare system resilience. Governments and health authorities increasingly recognize the value of innovative vaccine platforms that improve adherence and outcomes in adult populations. The acquisition highlights how industry consolidation, when aligned with regulatory oversight, can support broader access to critical vaccines, strengthen supply security, and advance evidence-based immunization strategies across healthcare systems.
With the planned acquisition of Dynavax, Sanofi is executing a strategic M&A move that integrates a marketed vaccine with differentiated science and a clinical-stage pipeline asset, reinforcing its leadership in vaccines across the lifespan. The convergence of scientific innovation, regulatory rigor, and global commercial infrastructure positions the combined portfolio to address significant unmet needs in adult infectious disease prevention. For cGxP.wire readers, the deal exemplifies how pharmaceutical M&A can drive compliant growth, manufacturing excellence, and sustained public health impact
Source: Sanofi Winthrop Industrie press release
